



- (51) **International Patent Classification:**
A61K 39/00 (2006.01) *A61K 38/12* (2006.01)
- (21) **International Application Number:**
PCT/US2024/023972
- (22) **International Filing Date:**
11 April 2024 (11.04.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/458,843 12 April 2023 (12.04.2023) US
- (72) **Inventors; and**
- (71) **Applicants:** BERGLUND, David [SE/US]; 400 W 61st St., Apt. 633, New York, NY 10023 (US). BERGLUND, Erik [SE/US]; 450 Washington Street, TH5, New York, NY 10013 (US).
- (74) **Agent:** MARTINEK, Sebastian et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** XENOGENEIC ANTIGEN PRESENTING CELLS AND USES THEREOF




FIG. 1

(57) **Abstract:** The present disclosure relates to methods for treating a tumor in a subject *via* administering (e.g. by intratumoral injection) a composition comprising antigen presenting cells obtained from a species that is different than the subject, *i.e.*, xenogeneic antigen presenting cells. The source of such xenogeneic antigen presenting cells could be one or more swine. The present disclosure also relates to methods of treating tumors *via* administering the xenogeneic antigen presenting cells in combination with other anti-cancer therapies. Furthermore, the present disclosure relates to pharmaceutical compositions comprising xenogeneic antigen presenting cells.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*